期刊文献+

转铁蛋白修饰的姜黄素脂质体的制备及体外抗肿瘤活性 被引量:6

Preparation and anti-tumor activity in vitro of transferrin modified curcumin liposomes
原文传递
导出
摘要 目的 制备转铁蛋白(transferrin,Tf)修饰的姜黄素(curcumin,Cur)脂质体(Tf-Cur-Lip),并研究其理化性质和体外抗肿瘤活性。方法 采用薄膜分散法制备Tf-Cur-Lip,对其形态、粒径、多分散性指数、包封率、载药量、体外释放等进行表征;以人前列腺癌DU154细胞为模型进行细胞抑制率实验与细胞摄取实验。结果 所制得的Tf-Cur-Lip呈类球形,大小分布均匀,平均粒径为(68.27±0.36)nm,多分散指数为0.194±0.050,平均包封率与载药量分别为(98.13±0.38)%与(2.94±0.38)%。体外释放研究表明,Tf-Cur-Lip相比游离姜黄素具有一定缓释效果。MTT实验结果表明Tf-Cur-Lip对DU145细胞的抑制作用显著高于游离姜黄素,与非靶向姜黄素脂质体(Cur-Lip)相比,转铁蛋白的修饰明显增加了DU145细胞对脂质体的摄取效率。结论 成功制备了Tf-Cur-Lip,该脂质体能够提高肿瘤靶向性,具有一定的抗肿瘤活性。 Objective To prepare transferrin(Tf) modified curcumin(Cur) liposomes(Tf-Cur-Lip) and evaluate its physicochemical properties and antitumor activity in vitro. Methods The Tf-Cur-Lip was prepared by thin film dispersion method, followed by characterization of the morphology, particle size, polydispersity index(PDI), encapsulation efficiency, drug loading amount and in vitro release. The anti-proliferative effect and cellular uptake of Tf-Cur-Lip were studied in DU145 cells. Results The prepared Tf-Cur-Lip showed spherical morphology, and the average particle size was(68.27 ± 0.36) nm and uniform distribution with narrow PDI was(0.194 ± 0.050). The encapsulation efficiency and drug loading amount were(98.13 ± 0.38)% and(2.94±0.38)%,respectively. The in vitro release studies showed that Tf-Cur-Lip has a sustained-release property compared with free Cur. MTT assay showed that the inhibitory effect of Tf-Cur-Lip on DU145 cells was significantly higher than that of free Cur. Tf-Cur-Lip showed significantly increased cellular uptake than curcumin-loaded liposomes(Cur-Lip) in DU145 cells. Conclusion Tf-Cur-Lip were successfully prepared, which can improve tumor targeting capability with enhanced anti-tumor activity.
作者 季珂 韩华 韩冰 梁绿圆 祝侠丽 关延彬 JI Ke;HAN Hua;HAN Bing;LIANG Lyu-yuan;ZHU Xia-li;GUAN Yan-bin(School of Pharmacy,Henan University of TCM,Zhengzhou 450040,China;School of Pediatrics,Henan University of TCM,Zhengzhou 450040,China)
出处 《中草药》 CAS CSCD 北大核心 2022年第18期5649-5656,共8页 Chinese Traditional and Herbal Drugs
基金 国家自然科学基金资助项目(81803740) 河南省科技攻关项目(182102310096) 河南省高等学校重点科研项目(18B360002) 河南省中医药科学研究专项课题(20-21ZY2150) 河南省高校国家级大学生创新创业训练计划项目(202110471009)。
关键词 姜黄素 转铁蛋白 脂质体 抗肿瘤活性 薄膜分散法 靶向性 curcumin transferrin liposome anti-tumor activity thin film dispersion method targeting
  • 相关文献

参考文献6

二级参考文献45

  • 1古炽明,潘明沃,陈志强,王树声,向松涛,李源,王志超,王昭辉.扶正抑瘤法治疗激素非依赖性前列腺癌临床疗效观察[J].时珍国医国药,2010,21(12):3239-3240. 被引量:12
  • 2Chen JG, Zhang SW. Liver cancer epidemic in China: past, present and future[J]. Seminars in Cancer Biology, 2011,21(1):59.
  • 3Jemal A, Bray F, Center MM, et al. Global cancer statis- tics[J]. CA CancerJClin, 2011, 61(2): 69.
  • 4Qin Y, Chen H, Zhang Q, et al. Liposome formulated with TAT-modified cholesterol for improving brain deliv- ery and therapeutic efficacy on brain glioma in animals [J]. Inter J Pharm, 2011,420 ( 2 ) : 304.
  • 5Zhang QY, Tang J, Fu L, et al. A pH-responsive a-heli- cal cell penetrating peptide-mediated liposomal delivery system[J]. Biomaterials, 2013,34 (32) : 7 980.
  • 6Yao Q, Chen H+ Yuan W, et al. Liposome formulated with TAT-modified cholesterol for enhancing the brain delivery [J]. Inter J Pharm, 201 I, 419 ( I ) : 85.
  • 7AI Soraj M, He L, Peynshaert K+ et al. siRNA and phar- macological inhibition of endocytic pathways to character- ize the differential role of macropinocytosis and the actincytoskeleton on cellular uptake of dextran and cationic cell penetrating peptides octaarginine (R8) and HIV-Tat [J]. J Control Release, 2012,161 ( 1 ) : 132.
  • 8Tang J, Zhang L, Liu Y, et al. Synergistic targeted deliv- ery of payload into tumor cells by dual-ligand liposomes co-modified with cholesterol anchored transferrin and TAT [J]. Inter J Pharm , 2013 , 454(1) : 31.
  • 9Gao H, Yang Z, Cao S, et al. Tumor cells and neo-vascu- lature dual targeting delivery for glioblastoma treatment [J]. Biomaterials, 2014,35 (7) : 2 374.
  • 10Yin Y, Wu X, Yang Z, et al. The potential efficacy of R8-modified paclitaxel-loaded liposomes on pulmonary arterial hypertension[J]. Pharm Res, 2013,30 (8) : 2 050.

共引文献34

同被引文献148

引证文献6

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部